Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

HSBC 'impressed' by quality of Elementis portfolio

(Sharecast News) - HSBC upgraded Elementis to 'buy' on Wednesday and lifted the price target to 170p from 150p as it said it was impressed by the company's portfolio quality and management execution "amid a challenging macro and weak end markets". The bank said any recovery could fillip to both growth and margins for Elementis.

"We think Elementis' portfolio has evolved into strong franchises with niche but leading positions with high margins and growth prospects," HSBC said. "Elementis also has long duration and differentiated resources in the form of the only hectorite clay mine in the world in California and talc deposits in Finland."

HSBC said the personal care business has strong cost advantages in the anti-perspirant actives, derives around 80% of raw materials from natural or naturally-sourced raw materials, and its foray in the skin and sun care markets is also bearing fruit.

"While its hectorite clay and talc-based applications in personal care and coatings will remain important, Elementis' new product launches, increasingly specialty focus and timely divestments have yielded fruit - gross profit margins reached historic highs of 45.8% in 2023," it said.

The bank noted that group adjusted EBIT margins were 14.6% in 2023 and it targets margins to improve to 19% over the medium term, aided by improving its product mix, reducing costs and a normalisation of demand trends.

"We think margins could continue to rise from here (we expect circa 17% in 2027) and upside risks exist if demand conditions support and management execution remains strong."

At 1005 GMT, the shares were up 1.8% at 144.40p.

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.